Brian McVeigh, Code Bio CEO

Take­da signs off on a $2B deal aimed at by­pass­ing AAV road­blocks on the way to gene ther­a­py 2.0

Take­da has tak­en an­oth­er step down the road to build­ing up its gene ther­a­py plat­form.

The phar­ma gi­ant an­nounced Tues­day morn­ing that it’s struck the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.